We translate condensate biology into much-needed medicines.
We believe that biomolecular condensates
- create dynamic, liquid compartments in cells
- concentrate important chemistry in space and time
- are central to neurodegeneration, cancer, and other diseases
- will help Dewpoint discover important new drugs
A new biology
Our founders and advisors explain how condensates drive cell function and solve biological mysteries.
Stressed cells form condensates.
Our impact
Condensates play a critical role in a wide range of important, once-intractable diseases. Dewpoint develops drugs that exploit this biology to hit “undruggable” targets.
Opportunities that excite us
- Neurodegeneration
- Cancer
- Inflammation
- Infectious disease
- Metabolic disease
- Rare genetic disorders
Collectively we have...
50
Marketed drugs
140+
Patents
800+
Papers
About us
We are a dynamic young biotech company based in Boston, Dresden, and Berlin that is translating brand-new insights about biomolecular condensates into treatments for the toughest diseases.
Latest News
Dewpoint strives to cultivate an inclusive international community that welcomes and empowers everyone. We reject racism, discrimination, harassment, brutality, and all other manifestations of hate.
We draw strength from diversity.
Join our team
We are looking for passionate—and compassionate—scientists across a diverse set of scientific disciplines, including cell biology, high content cell imaging, biophysics, and proteomics. If that’s you we’d love to hear from you, even if there’s not currently an opening that looks like a perfect fit.



Fascinating science
Mind-bending results that utterly change how we understand disease? That’s a Tuesday—and everybody on the team has a real say on what we do Wednesday.
Good folks
You know that jerk who made life in your last lab miserable? He doesn’t work here. But some of the nicest, smartest, goofiest people you’ll ever meet do.
Ambitious agenda
Interested in changing the way drug discovery is done while producing a whole new generation of treatments? Let's work together to make it happen.
Condensates.com
News, events, resources, and insights by and for the condensate community.
Visit siteCurated by
-
Two timescales control the creation of large protein aggregates in cells
Apr 2, 2021
-
Ultrasensitive Characterization of the Prion Protein by Surface-Enhanced Raman Scattering: Selective Enhancement via Electrostatic Tethering of the Intrinsically Disordered Domain with Functionalized Silver Nanoparticles
Apr 2, 2021
-
Liquid-to-solid phase transition of oskar RNP granules is essential for their function in the Drosophila germline
Apr 2, 2021
-
An improved molecular crowding sensor CRONOS for detection of crowding changes in membrane-less organelles under pathological conditions.
Apr 2, 2021
-
A designer FG-Nup that reconstitutes the selective transport barrier of the nuclear pore complex
Apr 1, 2021
-
New Insights into the Functions of Nucleic Acids Controlled by Cellular Microenvironments
Mar 31, 2021
-
Phase separation of RNA-binding protein promotes polymerase engagement and transcription
Mar 30, 2021
-
A FOXN1 mutation competitively displaces wild-type FOXN1 from higher-order nuclear condensates to cause immunodeficiency
Mar 30, 2021
-
SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA
Mar 30, 2021
-
Glycine rich segments adopt polyproline II helices: Implications for biomolecular condensate formation
Mar 30, 2021